Selinexor

Generic Name: Selinexor

Brand Names: Xpovio 100 Mg Once Weekly Carton, Nexpovio

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₁F_₆N_₇O

CAS Number: 1393477-72-9

Unique Ingredient Identifier: 31TZ62FO8F

Background: Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. Selinexor, in combination with bortezomib and dexamethasone, is currently approved for the treatment of multiple myeloma, a type of cancer formed from antibody-producing plasma cells. This condition is typically treated with high dose bortezomib and dexamethasone chemothe...

Indication: Selinexor is indicated in combination with bortezomib and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. Selinexor is also indicated in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma in adult patients who have received at least four prior therapi...

Associated Conditions: Multiple Myeloma (MM), Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Relapsed Diffuse large B-cell lymphoma NOS

Associated Therapies: -

Clinical Trials

Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma

Phase 4

Recruiting

Conditions: Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

Interventions: Drug: selinexor

First Posted Date: 2023-03-28

Last Posted Date: 2023-03-28

Lead Sponsor: Chongqing University Cancer Hospital

Target Recruit Count: 32

Registration Number: NCT05786989

Locations: 🇨🇳
Chongqing University Cancer Hospital, Chongqing, Chongqing, China

Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results

Phase 2

Recruiting

Conditions: MRD
AML

Interventions: Drug: Azacitidine
Drug: Venetoclax
Drug: Selinexor

First Posted Date: 2023-02-21

Last Posted Date: 2023-03-15

Lead Sponsor: Shanghai Tong Ren Hospital

Target Recruit Count: 58

Registration Number: NCT05736978

Locations: 🇨🇳
Pla Navy Feature Medical Center, Shanghai, China
🇨🇳
Shanghai Ruijin Hospital, Shanghai, China
🇨🇳
Shanghai Tong Ren hospital, Shanghai, China

and more 1 locations

A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia

Phase 2

Recruiting

Conditions: AML, Adult

Interventions: Drug: Selinexor
Drug: Azacitidine
Drug: Venetoclax

First Posted Date: 2023-02-21

Last Posted Date: 2023-03-15

Lead Sponsor: Shanghai Tong Ren Hospital

Target Recruit Count: 58

Registration Number: NCT05736965

Locations: 🇨🇳
Jilin University China Japan Union Hospital, Ch'ang-ch'un, China
🇨🇳
Changzhou Municipal No.1 People's Hospital, Changzhou, China
🇨🇳
Sichuan Provincial People's Hospital, Chengdu, China

and more 16 locations

Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia

Phase 3

Recruiting

Conditions: Relapsed or Refractory Acute Myeloid Leukemia

Interventions: Drug: Selinexor
Drug: Homoharringtonine
Drug: Daunorubicin
Drug: Cytarabine
Drug: Granulocyte Colony-Stimulating Factor
Drug: Aclacinomycin

First Posted Date: 2023-02-13

Last Posted Date: 2024-10-22

Lead Sponsor: Shanxi Bethune Hospital

Target Recruit Count: 50

Registration Number: NCT05726110

Locations: 🇨🇳
Tao Wang, Taiyuan, Shanxi, China

Selinexor in Combination With MTX+Ritu to Treat R/R CNSL

Phase 1

Recruiting

Conditions: Central Nervous System Lymphoma

Interventions: Drug: Selinexor
Drug: Rituximab
Drug: Methotrexate

First Posted Date: 2023-01-26

Last Posted Date: 2024-06-17

Lead Sponsor: Tong Chen, MD

Target Recruit Count: 30

Registration Number: NCT05698147

Locations: 🇨🇳
Oncology Department of The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳
Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳
The First Affiliated Hospital Of Fujian Medical University, Fuzhou, Fujian, China

and more 2 locations

Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Phase 3

Recruiting

Conditions: Endometrial Cancer

Interventions: Drug: Matching Placebo for selinexor
Drug: Selinexor

First Posted Date: 2022-11-10

Last Posted Date: 2024-07-24

Lead Sponsor: Karyopharm Therapeutics Inc

Target Recruit Count: 220

Registration Number: NCT05611931

Locations: 🇺🇸
The University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Honor Health, Phoenix, Arizona, United States
🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

and more 163 locations

Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma

Phase 2

Recruiting

Conditions: Smoldering Multiple Myeloma

Interventions: Drug: Selinexor

First Posted Date: 2022-10-28

Last Posted Date: 2023-10-17

Lead Sponsor: University of Rochester

Target Recruit Count: 15

Registration Number: NCT05597345

Locations: 🇺🇸
University of Rochester, Rochester, New York, United States

Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients

Phase 1

Recruiting

Conditions: EBV-Positive Diffuse Large B-Cell Lymphoma, Nos

Interventions: Drug: Selinexor
Drug: R-CHOP Protocol

First Posted Date: 2022-10-13

Last Posted Date: 2023-12-14

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 54

Registration Number: NCT05577364

Locations: 🇨🇳
Sun Yat-sen Universitiy Cancer Center, Guangzhou, Guangdong, China
🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma

Phase 2

Recruiting

Conditions: Relapsed and Refractory Multiple Myeloma

Interventions: Drug: Selinexor
Drug: Venetoclax
Drug: Dexamethasone

First Posted Date: 2022-09-07

Last Posted Date: 2024-03-13

Lead Sponsor: University of Miami

Target Recruit Count: 33

Registration Number: NCT05530421

Locations: 🇺🇸
University of Miami, Lennar Foundation Medical Center, Coral Gables, Florida, United States
🇺🇸
University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸
University of Miami, Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida, United States

Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

Phase 1

Recruiting

Conditions: MGMT-Methylated Glioblastoma
Recurrent Glioblastoma, IDH-Wildtype
Recurrent MGMT-Methylated Glioblastoma

Interventions: Procedure: Biospecimen Collection
Procedure: Magnetic Resonance Imaging
Drug: Temozolomide
Drug: Selinexor

First Posted Date: 2022-06-27

Last Posted Date: 2024-12-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 97

Registration Number: NCT05432804

Locations: 🇺🇸
University of Chicago Medicine-Orland Park, Orland Park, Illinois, United States
🇺🇸
Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

and more 31 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy